Noranelle (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Noranelle, is a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It is indicated for prevention of pregnancy in women of reproductive age and may also be used to regulate menstrual cycles and to provide cycle control.

GNH USA supplies Noranelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. All batches are manufactured under GMP conditions and undergo rigorous testing before release.

Noranelle, a combined estrogen‑progestogen oral contraceptive, is used within the hormonal contraception pathway to prevent unintended pregnancy.

- Contraception: prevents ovulation and pregnancy in women of childbearing age. - Menstrual cycle regulation: provides predictable bleeding patterns and reduces menstrual flow. - Acne management: decreases androgen‑driven skin lesions in women when prescribed for this indication.

Noranelle may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Liver tumor

Before prescribing Noranelle, clinicians should evaluate several safety considerations.

- Assess thrombotic risk: avoid in women with history of venous thromboembolism or known clotting disorders. - Evaluate cardiovascular status: contraindicated in smokers over 35 years and in patients with uncontrolled hypertension. - Review hepatic function: use with caution in liver disease and discontinue if severe hepatic impairment occurs. - Consider hormonal contraindications: not suitable for women with estrogen‑dependent tumors or unexplained vaginal bleeding. - Drug interactions: check for concomitant use of enzyme‑inducing medications that may reduce efficacy. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Noranelle can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone levels, raising risk of side effects. - Certain antiretrovirals (e.g., protease inhibitors boosted with ritonavir): may affect hormone metabolism.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., sertraline, fluoxetine): may increase bleeding risk. - Anticonvulsants with moderate enzyme induction (e.g., valproic acid): may modestly lower effectiveness. - Herbal supplements (e.g., St. John’s wort): may decrease plasma concentrations.